Literature DB >> 17223653

Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.

José A Gómez-Puerta1, Ricard Cervera, Gerard Espinosa, Ronald A Asherson, Mario García-Carrasco, Izaias P da Costa, Danieli C O Andrade, Eduardo F Borba, Alexander Makatsaria, Silvia Bucciarelli, Manuel Ramos-Casals, Josep Font.   

Abstract

BACKGROUND: The catastrophic variant of the antiphospholipid syndrome (APS) is a life-threatening form of presentation of this syndrome that can be triggered by several factors. AIM: To describe the characteristics of patients who developed catastrophic APS triggered during pregnancy and puerperium.
METHODS: A review of the first 255 cases collected in the website-based "CAPS Registry" was undertaken. Three new and unpublished cases of catastrophic APS developed during pregnancy and puerperium were added.
RESULTS: Fifteen cases were identified. The mean (range) age was 27 (17-38) years. Most patients had a previous unsuccessful obstetric history. In 7 of 14 (50%) cases with available medical history, the catastrophic APS appeared during pregnancy, in 6 (43%) during the puerperium and in 1 (7%) after curettage for a fetal death. The main clinical and serological characteristics were similar to those patients with catastrophic APS triggered by other factors, except for a history of a higher prevalence of previous abortions (p<0.01). Several specific features were found, including the HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome in 8 (53%) patients, placental infarctions in 4 (27%) patients, and pelvic vein thrombosis and myometrium thrombotic microangiopathy in 1 (7%) patient each. Mortality rate was high for the mothers (46%), and for the babies (54%).
CONCLUSIONS: It is important to consider the possibility of the development of catastrophic APS in those patients with signs of HELLP syndrome and multiorgan failure during pregnancy or puerperium, especially in those patients with previous history of abortions and/or thrombosis.

Entities:  

Mesh:

Year:  2007        PMID: 17223653      PMCID: PMC1954660          DOI: 10.1136/ard.2006.061671

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  28 in total

1.  Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets.

Authors:  G F von Tempelhoff; L Heilmann; E Spanuth; E Kunzmann; G Hommel
Journal:  Thromb Res       Date:  2000-11-15       Impact factor: 3.944

2.  Successful treatment of catastrophic antiphospholipid syndrome in a pregnant woman.

Authors:  M Wislowska
Journal:  Clin Exp Rheumatol       Date:  1999 Mar-Apr       Impact factor: 4.473

3.  [Catastrophic antiphospholipid syndrome in the immediate puerperium].

Authors:  P Ortiz; A Castro; M Vallés; E Coll; M Casas; J M Mauri
Journal:  Nefrologia       Date:  2003 Sep-Oct       Impact factor: 2.033

Review 4.  Venous thromboembolism during pregnancy.

Authors:  M R Toglia; J G Weg
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

Review 5.  Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.

Authors:  R A Asherson; R Cervera; J C Piette; J Font; J T Lie; A Burcoglu; K Lim; F J Muñoz-Rodríguez; R A Levy; F Boué; J Rossert; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  1998-05       Impact factor: 1.889

6.  Bone marrow necrosis and refractory HELLP syndrome in a patient with catastrophic antiphospholipid antibody syndrome.

Authors:  Jayashree Sinha; Iftikhar Chowdhry; Sarah Sedan; Peter Barland
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

Review 7.  Thrombotic storm: when thrombosis begets thrombosis.

Authors:  C S Kitchens
Journal:  Am J Med       Date:  1998-04       Impact factor: 4.965

8.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo
Journal:  Arthritis Rheum       Date:  2002-04

Review 9.  Antiphospholipid syndrome: obstetric diagnosis, management, and controversies.

Authors:  D Ware Branch; Munther A Khamashta
Journal:  Obstet Gynecol       Date:  2003-06       Impact factor: 7.661

Review 10.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

View more
  16 in total

1.  Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge.

Authors:  Victoria Sadick; Stuart Lane; Eddy Fischer; Ian Seppelt; Anita Shetty; Anthony McLean
Journal:  J Intensive Care Soc       Date:  2018-03-19

2.  The HELLP syndrome, antiphospholipid antibodies, and syndromes.

Authors:  Ronald A Asherson; Claudio Galarza-Maldonado; Jose Sanin-Blair
Journal:  Clin Rheumatol       Date:  2007-10-03       Impact factor: 2.980

3.  Partial HELLP syndrome in pregnancy complicated by recurrent deep vein thromboses and palmar skin lesions in a patient with prothrombin gene 20210a mutation and antiphospholipid antibodies: an unusual case.

Authors:  Ronald A Asherson; Cathy Spargo; Jose A Gómez-Puerta
Journal:  Clin Rheumatol       Date:  2007-07-03       Impact factor: 2.980

4.  Pregnancy and catastrophic antiphospholipid syndrome.

Authors:  Jose A Gómez-Puerta; Jose Sanin-Blair; Claudio Galarza-Maldonado
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  Incidence of anticardiolipin antibodies and lupus anticoagulant factor among women experiencing unexplained recurrent abortion and intrauterine fetal death.

Authors:  Noura Al Jameil; Poonam Tyagi; Amal Al Shenefy
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 6.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

7.  Rare Presentation of Catastrophic Antiphospholipid Syndrome with Myocarditis in Post-partum Period: Case Report and Review of Literature.

Authors:  Bhavana Girish; Shalini Gainder; S C Saha; Darshan Krishnappa
Journal:  J Obstet Gynaecol India       Date:  2017-02-22

Review 8.  Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome.

Authors:  Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

9.  Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Authors:  Nataliya Mar; Rebecca Kosowicz; Karen Hook
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 10.  Organ Damage and Quality of Life in Antiphospholipid Syndrome.

Authors:  P Alba; J A Gómez-Puerta; M V Goycochea-Robles; M C Amigo
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.